Review

Mitochondria in Ischemic Stroke: New Insight and Implications

Fan Liu¹, Jianfei Lu¹, Anatol Manaenko², Junjia Tang³, Qin Hu¹,*

¹Discipline of Neuroscience, Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
²Departments of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany
³Department of neurosurgery, Shanghai General Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China

[Received October 10, 2017; Revised November 25, 2017; Accepted November 26, 2017]

ABSTRACT: Stroke is the leading cause of death and adult disability worldwide. Mitochondrial dysfunction has been regarded as one of the hallmarks of ischemia/reperfusion (I/R) induced neuronal death. Maintaining the function of mitochondria is crucial in promoting neuron survival and neurological improvement. In this article, we review current progress regarding the roles of mitochondria in the pathological process of cerebral I/R injury. In particular, we emphasize on the most critical mechanisms responsible for mitochondrial quality control, as well as the recent findings on mitochondrial transfer in acute stroke. We highlight the potential of mitochondria as therapeutic targets for stroke treatment and provide valuable insights for clinical strategies.

Key words: Ischemic stroke, mitochondrial quality control, mitophagy, mitochondrial transfer, neuroprotection

1. Introduction

Stroke is one of the leading causes of morbidity and mortality worldwide. More than 80% of strokes are ischemic and are caused by obstruction of one or more cerebral arteries [1, 2]. Lack of blood supply deprives the brain cells of necessary glucose and oxygen, and disturbs cellular homeostasis, culminating in neuronal death. Currently, tissue plasminogen activator (tPA) is the only effective pharmacological therapy approved by the Food and Drug Administration for acute ischemic stroke since 1996, but its use remains limited due to the narrow therapeutic window [3-6]. It is imperative to develop novel therapeutic strategies of stroke [7, 8].

Mitochondria, as the powerhouse of cell, play a critical role in cell energy homeostasis and are thus inevitably involved in the ischemic neuronal death. After ischemia, due to the reduced blood supply, the energy balance is disrupted and adenosine triphosphate (ATP) synthesis is disturbed. In addition to their fundamental role in energy generation, mitochondria are critical involved in the regulation of such forms of cell death as apoptosis, autophagy and necroptosis. Mitochondrial dysfunction has been regarded as one of the hallmarks of ischemia/reperfusion (I/R) injury which induces neuronal death[9]. Accumulating evidences indicate that the maintaining of the mitochondrial function is crucial for neuron survival and neurological improvement. Therefore, targeting mitochondria is one of the promising neuroprotective strategies for stroke treatment [10].
Recently, it has been demonstrated that mitochondria can be transferred from astrocytes to neurons and served as “help-me signaling” in cell-to-cell communication after cerebral ischemia [11]. In this review, we will discuss current knowledge on the role of mitochondria in cell death and cell survival, and highlight the advance of mitochondria-based therapy in stroke. In particular, we will emphasize the most critical mechanisms responsible for mitochondrial quality control, as well as the recent findings on mitochondrial transfer in acute ischemic stroke.

2. Pathophysiology of ischemic stroke

Ischemic stroke is a consequence of a critical reduction of regional cerebral blood flow (rCBF), leading to severe oxygen and glucose deprivation. Mitochondrial disfunction induced by oxygen and glucose deprivation occurs within minutes after ischemia, resulting in depletion of ATP production and overproduction of reactive oxidative species (ROS). Compared to other brain cells, neurons have higher energy demand, but their energy reserves are limited. Depletion of ATP is one of the major initiators, which triggers the ischemic cascades such as, membrane ion pump failure, efflux of cellular potassium, influx of sodium, chloride and water, and membrane depolarization [12-14]. Multiple mechanisms, including excitotoxicity, mitochondrial response, free radical release, acidotoxity, protein misfolding, and inflammation have been extensively studied as the events leading to the cellular death and neuronal loss after stroke [15-17], which are depicted in Fig. 1.

![Figure 1. Mechanisms underlying neuronal death in ischemic stroke.](image-url)

(1) Mitochondrial response, including excessive ROS production, mitochondrial calcium overloading, and disrupted mitochondria quality control. (2) Excitotoxicity. Excessive glutamate release and impeded reuptake of excitatory amino acids result in the activation of NMDARs, AMPARs and KARs. (3) Acidotoxicity. Extracellular acidification leads to ischemic neuronal death by activating acid-sensing ion channel 1a (ASIC1a). (4) Protein misfolding. Protein misfolding and aggregation are observed after brain ischemia. (5) Inflammatory reaction. Microglia are activated and release cytokines and chemokines to induce inflammation reaction. All the factors mentioned above work synergistically to trigger cell death pathways such as apoptosis, necroptosis and autophagy. ROS: reactive oxygen species; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor; NMDAR: N-methyl-D-aspartate receptor; KAR: kainite receptor; DAPK1: death associated protein kinase 1; PSD95: postsynaptic density protein 95; ASIC1a: acid-sensing ion channel 1a; RIPK1: receptor interacting protein kinase 1; TNF-α: tumor necrosis factor-α; IL-6: Interleukin 6; IL-1: Interleukin 1.
Table 1. Mitochondrial dynamic-related proteins.

| Mammals | Yeast | Role in mitochondria dynamics | Location |
|---------|-------|-------------------------------|----------|
| Drp1    | Dnm1p | Fisson                        | cytosolic, and recruited to outer membrane during fission |
| Fis1    | Fis1p | Fisson                        | Outer mitochondrial membrane |
| Endophilin B1 | -     | Fisson                        | cytosolic, and recruited to outer membrane during fission |
| Mfn1/2  | F201p | Fusion                        | Outer mitochondrial membrane |
| Opa1    | Mgm1p | Fusion                        | Inner mitochondrial membrane |
| KIFs    |       | Transport                      | Cytosolic |
| Cytoplasmic dynein | Dynclil | Transport                      | Cytosolic |

There are two major zones of injury in ischemic brain: the infarct core and the ischemic penumbra. The “infarct core” is the area with the blood flow decline below the threshold of energy failure (15%–20%). The “infarct core” will be irreversibly damaged during few minutes after stroke and cannot be salvaged [18]. On the contrary, ischemic penumbra is the region with impaired functions, but preserved structure integrity [19]. Cells in penumbra are salvageable if reperfusion is established during the early hours or collateral circulation is adequate to maintain the neuronal demand for oxygen and glucose [15]. Therefore, the penumbra is the pharmacological target for the treatment of acute ischemic stroke.

In the infarct core, neuronal cells undergo necrotic alterations, which are accompanied by glutamate release and excitotoxic cell damage to neighboring regions [20]. The penumbra is moderately hypoperfused and energy metabolism is partially preserved, which transiently sustain tissue viability. Timely interventions are effective to avoid the progression of the penumbra into infarction. The molecular mechanisms leading to the cell death in the penumbra differ from those in the infarct area. Several types of regulated cell death such as autophagy, apoptosis, necroptosis, and pyroptosis can be triggered by ischemia and contribute to the post stroke brain injury. To some extent, different kind of cell death can cross-regulate each other [21, 22]. Mitochondria can be considered as one of the master regulators of stress signaling [23-26] (Fig. 2). The impairment of mitochondrial respiratory function and membrane potential activate the cascade of events that leads to neuronal death after ischemia. Depolarized mitochondria initiate excessive ROS production, decreased ATP generation, PTEN-induced putative kinase 1 (PINK1) accumulation, as well as unfolded protein response (UPR) [27]. The increased levels of ROS and overloading calcium open the membrane permeability transition pore allowing for the release of cytochrome c, which activates the effector caspases and the final execution of apoptotic death [28]. PINK1 selectively recruits Parkin and phosphorylates both Parkin and ubiquitin to trigger mitophagy [29]. Interruption of the signaling pathways is apparently able to disrupt, or in some instances greatly delay, the spiral of increasingly vicious reactions that culminate in cell death.

Figure 2. Mitochondria play a central role in ischemic neuronal death. Ischemia triggers the depolarization of mitochondrial membrane potential (ΔΨm), reduction of ATP production, accumulation of PINK1, recruitment of Parkin, overproduction of reactive oxygen species (ROS), overloading of matrix calcium, and opening of mitochondrial permeability transition pore (mPTP), eventually leading to neuronal death.

3. Structure and function of mitochondria

Mitochondria are ovoid or rod-shaped organelles with double-membrane structure, which consist of four distinct compartments – the outer membrane, the intermembrane space, the inner membrane, and the matrix [30]. The outer membrane contains a number of pores which form large
Mitochondria in Ischemic Stroke

4. Mitochondrial quality control systems and ischemic stroke

4.1 Mitochondria quality control systems

Mitochondria control virtually every aspect of cell function, including managing redox status, modulating Ca^{2+} homeostasis, generating ATP, and regulating response to cellular and environmental stresses. Over the last decade, mitochondria have moved to the forefront of cell biology research for their central role in regulation of cell death signaling. In stroke, abnormalities in mitochondrial membrane potential and ROS overproduction induce neuronal injury (Fig. 2). Here we focus on the most recent findings on the role of mitochondrial quality control processes especially regulation of dynamics and mitophagy in stroke, highlighting their potential as therapeutic targets.

Neuronal survival critically depends on the integrity and functionality of mitochondria. A hierarchical system of cellular surveillance mechanisms protects mitochondria against stress and damage, hence ensures the selective removal of dysfunctional mitochondrial proteins. There are 3 levels of well-conserved mitochondria quality control mechanisms [35]. The first level of defense involves a multilayer network of detoxifying systems capable of fighting oxygen- and aldehyde-mediated mitochondrial toxicity. The second level of defense relies to mitochondrial proteases and chaperones responsible for the maintenance of mitochondrial proteostasis. Toxic folding intermediates or the accumulation of aggregates are deleterious for the cells and it is imperative to correct protein folding and maintain cellular homeostasis. The third level of defense involves the control of mitochondrial morphology, quantity of mitochondria through mitochondrial dynamics (fusion and fission) and mitophagy (mitochondrial clearance). Maintaining mitochondrial integrity and elimination of damaged mitochondria are important avenues to preventing widespread mitochondrial dysfunction, oxidative stress, and cell death in ischemic insult. Hence, mitochondrial dynamics and mitophagy play critical roles in maintaining cellular homeostasis and function. Here we will focus on the third level of defense in response to ischemic stress.

4.2 Mitochondrial dynamics and ischemic stroke

Mitochondria are highly dynamic cellular organelles characterized by their ability to change size, shape and location through highly coordinated processes of fission (separation of a single mitochondrion into two or more daughter organelles), fusion (the opposing reaction) and transport to strategic locations [36-38]. Healthy mature neurons with established synaptic connections exhibited longer, more stationary mitochondria whereas impaired or immature neurons have smaller, more motile mitochondria. Mitochondrial fusion and fission were first observed in yeast in 1994. By now it is known that these processes play critical roles in maintaining mitochondrial integrity and function of cells when experiencing metabolic or environmental stresses [39]. Mitochondrial fusion allows the rapid exchange of mitochondrial membranes, mitochondrial DNA (mtDNA), and mitochondrial metabolites within a mitochondrial network; while damaged mitochondria can be repaired through fusion with healthy mitochondria for integrating of contents and promotes cell survival by complementation. On the other hand, mitochondrial fission enables the segregation of damaged mitochondria and leads to their subsequent elimination via mitophagy [40]. Fission and fusion are active processes which require many specialized large guanosine triphosphatases (GTPases). Dynamin-related protein 1 (Drp1), Fis1 and...
Endophilin B1 are required for mitochondrial fission in mammals; Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2) and Opa1 are responsible for fusion. Kinesin superfamily proteins (KIFs) and cytoplasmic dynein are the main microtubule-based motor proteins ensure targeted trafficking of mitochondria and precise regulation of their mobility [41] (Table 1). In neurons, mitochondrial fission is essential for mitochondrial transport to their potential docking sites in axons and dendrites. Defects in mitochondrial fusion, fission or transport lead to impaired mitochondrial motility and function in neurons (Fig. 3). In neuroglial cells, alteration in mitochondrial dynamics contribute to the differential functions of reactive microglia in neurological diseases [42, 43]; and in astrocytes, proinflammatory stimuli induced mitochondrial fission, and ultimately bioenergetics to maintain mitochondrial network [44].

Previously the molecular machineries of mitochondrial fission and fusion were studied separately. Currently, more and more researchers are interested in investigating the coordination/balance of mitochondria dynamics. Mitochondrial fission protein Drp1 was observed to affect the activity of fusion. Santel’s group found that the depletion of Drp1 resulted in reduction of Mfn1, Mfn2 and Opa1 in Hela and HUVEC cells [45]. Consistent with their work, Saita et al reported that loss of Drp1 led to the degradation of Mfn1 via the ubiquitin-proteasome system [46]. These studies indicated that in addition to the canonical roles of Drp1 in mitochondrial fission, it also acts as regulatory factors that control mitochondrial fusion. Furthermore, Anand et al reported that expression of mitochondrial fusion protein Opa1 unexpectedly triggered mitochondrial fragmentation in Yme1lac cells and HEK293T cells, which suggests that mitochondrial fusion protein Opa1 is associated with fission [47]. The coordination of fusion proteins and fission proteins are responsible for fine-tuning mitochondrial dynamics and cell sensitivity to stress.

It is well documented that in ischemic brain injury mitochondrial dynamics are closely linked to their morphology and functions. Mitochondrial fission is an early event required for ischemic neuronal death, which is mediated by Drp1 and Mfn1/2 [48-50]. In primary cultured cortical neurons, nitric oxide exposure triggered dose-dependent mitochondrial fission and caused ultrastructural damage, which are associated with bioenergetic failure and increased ROS production. After middle cerebral artery occlusion (MCAO) in mice, mitochondrial fission occurs as early as 3 h after
In the ischemic penumbra, the protein level of both Drp1 and Opal increased at 2 days after MCAO, and returned to the baseline at day 7. In the ischemic core, however, the expression of Drp1 and Opal progressive decreased until 2 days after transient MCAO [51]. Hyperglycemia further enhanced mitochondrial fission by increasing protein levels of Drp1 and Fis1, as well as decreasing the level of Opal in MCAO mice [52]. By contrast, the expression of mitochondrial fusion protein Mfn2 decreased in both in vivo and in vitro ischemic models, and reduced Mfn2 expression led to mitochondrial dysfunction and disruption of Ca²⁺ homeostasis [49, 50]. Using transgenic mice expressing mitochondria targeted yellow fluorescent protein (mito-eYFP), Owens and his colleagues examined cell-type specific changes of mitochondrial dynamics in hippocampal region following global cerebral ischemia in mice [53]. In cornuammonis 1 (CA1) area of hippocampus, mitochondrial fragmentation started as early as 2 h after the reperfusion and reached the peak at 24 h. Similar observations were done in the CA3 and dentate gyrus (DG) area; however, mitochondria in CA3 and DG neurons started to refuse after 24 h of reperfusion; astrocytes underwent transient mitochondrial fission from 2 h after ischemia and regained their normal shape at 24 h of recovery [53]. Their data first suggested that ischemia resistant neurons were able to shift their mitochondrial dynamics toward fusion after extensive fragmentation. Recently, using in vivo two-photon microscopy, Kislin et al visualized the fragmentation of neuronal mitochondria in the living mouse brain [54]. They induced severe global ischemia by bilateral common carotid artery occlusion, furthermore they induced severe focal stroke injury by Rose Bengal photosensitization and moderate and mild traumatic brain injury by focal laser lesion or mild photo-damage respectively. Mild injury induced transient mitochondrial fragmentation and decreased dendritic spine density, however, severe brain ischemia caused mitochondrial fragmentation and dendritic damage. Their findings showed that alterations of mitochondrial morphology were very sensitive to ischemia and were reversible in moderate and mild injury [54].

Table 2. Chemical agents targeting mitochondrial dynamics in ischemic stroke

| Agents                   | Proposed mechanisms                                      | Refs.     |
|--------------------------|----------------------------------------------------------|-----------|
| Drp1 siRNA               | Inhibition of fission via DRP1 down-regulation            | [55-57, 61]|
| Drp1 cysteine mutation   | Inhibition of fission by preventing S-nitrosylation induced Drp1 activation | [59]      |
| Ginkgolide K             | Inhibition of fission by increasing Drp1 phosphorylation and inhibiting Drp1 recruitment | [60]      |
| mdivi-1                  | Inhibition of fission by inhibiting the GTPase activity of Drp1 | [55, 61]  |
| P110                     | Inhibition of fission by inhibiting Drp1 enzyme activity and blocking Drp1/ Fis1 interaction | [62, 63]  |
| Mfn2 overexpression      | Promotion of fusion                                      | [49, 50]  |

Pharmacological agents or genetic interventions that either inhibiting fission or promoting fusion generally protect neurons from ischemic injury (Table 2). Down-regulation or inhibition of Drp1 reduced mitochondrial fission and maintained normal mitochondrial morphology and function in ischemic neurons [55-57]. Drp1 siRNA and small molecule inhibitors of Drp1 prevented mitochondrial fission, loss of mitochondrial membrane potential, and cell death in glutamate toxicity or OGD in vitro, and after ischemic brain damage in vivo [57]. However, Drp1 knockout caused embryonic lethality in mice [58]. Drp1 was activated by S-nitrosylation and this process can be prevented by cysteine mutation to protect mitochondria from fragmentation [59]. Ginkgolide K, a natural compound found in Ginkgo biloba leaves, attenuated neuronal apoptosis in OGD model by increasing Drp1 phosphorylation at Ser637 and inhibiting Drp1 recruitment [60]. Mitochondrial division inhibitor mdivi-1, a selective inhibitor of mitochondrial fission protein Drp1, protected brain from OGD reperfusion.
injury and MCAO through suppressing the ROS production and decreasing the expression of cytochrome C [55, 61]. P110, a novel and selective peptide inhibitor of mitochondrial fission, inhibited Drp1 enzyme activity and blocked Drp1/ Fis1 interaction [62]. It abolished Drp1-dependent p53 stabilization on mitochondria and reduced brain infarction in rats subjected to brain ischaemia/ reperfusion injury [63]. Promoting mitochondrial fusion also protects cell from injury. Mfn2 overexpression attenuated mitochondrial dysfunction and restored mitochondrial morphology [49, 50]. Interestingly, treadmill exercise pretreatment enhanced mitochondrial fusion via up-regulation of Opa1 after cerebral ischemia [64].

4.3 Mitophagy and its role in ischemic stroke

Mitophagy was first described by Lemasters and colleagues in 2005, who determined that mitophagy is an autophagic response, which is responsible for specifically removal of damaged mitochondria to maintain mitochondria homeostasis [65]. The molecular mechanisms regulating mitophagy were originally characterized in yeast. Uth1p and Aup1p are two major proteins required for mitophagy in nutrient deprivation or stationary phase, respectively [66, 67]. However, the corresponding mammalian homologues of Uth1p and Aup1p are yet to be identified. The mechanisms of mitophagy in mammalian cells can be generally classified as ubiquitin (Ub)-dependent and Ub-independent pathways. Theserine/threonine kinase PINK1 and the E3 ligase Parkin pathway is currently the best understood Ub-dependent mechanism of mitophagy for the recognition of damaged mitochondria [68].

Recently mitophagy has received increasing attention in stroke and has been evidenced in in vivo models and in cultured neurons. In ischemic stroke, mitophagy could be predominantly mediated by PINK1/Parkin pathway. However, the role of mitophagy in the development of ischemic brain injury remains controversial. Accumulating data have showed that mitophagy is a double-edged sword that can be protective or destructive after experimental stroke [69-73]. Most studies support the hypothesis that mitophagy favors neurons adapted to the stress by removing impaired mitochondria and suppressing cell death signaling cascades. These studies proposed that mitophagy is a promising therapeutic target for stroke treatment. In permanent MCAO, mitophagy was triggered at as early as 1 hour and involved in the removal of damaged mitochondria and cellular survival in a Drp1-dependent way [74]. Mitophagy was also activated in the reperfusion phase after MCAO and contributed to the inhibition of post stroke apoptosis [69]. Rapamycin treatment improved mitochondrial function through enhancing mitophagy after experimental ischemic stroke [75]. The neuroprotective role of methylene blue in acute cerebral ischemia can also be explained by promoting mitophagy and maintaining the mitochondrial membrane potential, which consequently decreased necrosis [76]. Melatonin-mediated mitophagy attenuated the early brain injury after subarachnoid hemorrhage through inhibition of NLRP3 inflammasome activation [77]. Mitophagy also contributed to the neuroprotection induced by limb remote ischemic conditioning after ischemic stroke [73]. The destructive role of mitophagy after cerebral ischemia has also been reported [70, 71]. Inhibition of mitophagy by decreasing p-Drp1 and Parkin mediated the neuroprotective effects of carnosine in rats after MCAO[70], and excessive induction of mitophagy leads to cell death in neonatal stroke[71]. The harmful roles of mitophagy in stroke have not been adequately emphasized. Further investigations are required to understand whether mitophagy is beneficial or detrimental after stroke. It appears that the effects of mitophagy depend on the severity of it. While physiological or mild levels of mitophagy favor the neuronal survival, intensive or excessive levels could be lethal and exacerbate the ischemic brain injury.

5. Intercellular Mitochondrial transfer

5.1 Intercellular mitochondrial transfer and potential mechanisms

For a long time, mitochondria were considered to be retained intracellularly for their lifetime. Recently, intercellular exchange of membrane vesicles and organelles through structures such as tunneling nanotubes (TNT) or microvesicles has been evidenced [78, 79]. Mitochondrial transfer has been observed in several cardiovascular injury models, and has also been demonstrated in experimental stroke [11, 80, 81]. In 2006 the horizontal transfer of mitochondria, from human mesenchymal stem cells (MSCs) to somatic cells in vivo was shown by Prockop’s lab [82]. Furthermore, it has been documented that intercellular mitochondrial transfer occurs in different cell types both in vitro and in vivo [11, 80, 81, 83-87]. MSCs are indicated as the most popular donator for mitochondrial transfer. Many studies suggest that transfer of mitochondria from one cell to another is a protective mechanism accountable for rescue of injured cells from mitochondrial dysfunctions in response to stress [11, 88, 89]. When co-cultured with mitochondria dysfunctional somatic cells, human MSCs developed cytoplasmic projections and steamed mitochondria to
Figure 4. Intercellular mitochondrial transfer. Mitochondria can be released by donate cells and uptake by recipient cells. Stressed or dying cells release mitochondria through tunneling nanotubes (TNTs) or microvesicles. Mitochondrial transfer can occur between same or different cell types.

The mechanisms underlying mitochondria release and uptake by recipient cells are still unclear. Stressed cells or dying cells release mitochondria serving as danger warning signals. When stimulated with tumor necrosis factor alpha (TNF-α), mouse embryonic fibroblasts and hepatocytes extruded mitochondria through autolysosomal exocytosis [90]. In human T-lymphoblastic leukemia cells and murine fibroblast cells, TNF-α induced necroptosis was accompanied by extracellular release of mitochondria [91]. This is an active process, which occurs before the disruption of the plasma membrane. The mitochondria were intact and no mtDNA was emitted. Several molecular mechanisms have been proposed to regulate intercellular mitochondrial transfer. A study by Ahmad and his colleagues reported that Miro1 promoted mitochondrial transfer from MSCs to epithelial cells, which was well-directed rather than a general exchange of contents [92]. In human acute myeloid leukemia, ROS drives TNTs formation and regulates the transfer of mitochondria from bone marrow stromal cells to leukemia blasts through NADPH oxidase-2 [93]. Astrocytic release of extracellular mitochondria was mediated by a calcium-dependent mechanism involving CD38 and cyclic ADP ribose signaling in ischemic stroke mice, and integrin-mediated Src/Syk signaling might be involved in the endocytosis of mitochondria in neurons [11]. Several other studies suggested that macrophage cells and immune cells recognized the released mitochondria by damage-associated molecular patterns [27, 91, 94]. However, the health status and the fates of the transferred mitochondria before/after internalization were not assessed in these studies. Recently, using mitochondrial reporter mitoROGFP, which is able to detect oxidative stress, Melentijevic et al showed that stressed or damaged mitochondria were preferentially extruded in adult neurons from Caenorhabditis elegans [88]. Human macrophages and dendritic cells engulfed released mitochondria and triggered the secretion of proinflammatory cytokines [91]. In a co-culture system of MSCs with cardiomyocytes or endothelial cells subjected to oxidative challenge with hydrogen peroxide (H₂O₂), mitochondria from suffering cells were engulfed and
degraded by MSCs, leading to induction of the cytoprotective enzyme heme oxygenase-1 and stimulation of mitochondrial biogenesis [95]. Such studies have revealed that organelles can function as a new aspect of transcellular signaling like moleculars, which opens an entirely new perspective on cell-to-cell communication (Fig. 4). Elucidation of the mechanisms of mitochondrial transfer will help to establish therapy-based mitochondrial restoration for human diseases caused by mitochondrial dysfunction.

5.2 Mitochondrial transfer techniques and its application in ischemic stroke

In 1982, Clark and Shay first transferred mitochondria with antibiotic-resistant genes to sensitive cells, which enabling the cells to survive in a selective medium [96]. Their observations opened the new field of research on mitochondrial transfer. Various approaches have been developed to replenish the damaged mitochondria in recipient cells and suggest new possible applications. Coincubation is the first and simple approach tested and the efficiency differs in different cell lines [96]. Microinjection and such other invasive techniques as nanoblades can quickly repopulate the resident mtDNA, but they are less efficient than coincubation for the limited cell numbers [97, 98]. Additional techniques has been developed to facilitate the mitochondria internalization into the recipient cells, for example, conjugating the mitochondria with cell-penetrating peptide Pep-1, labeling mitochondria with anti-TOM22 magnetic beads, and increase of mitochondrial uptake by MitoCeption technique [99-101]. In the in vivo studies, mitochondria were either directly injected into the ischmic heart or delivered intracoronarly at the onset of reperfusion in rabbits [102, 103]. Both two methods effectively decreased the infarct size and restored the heart functions. In ischemic stroke, direct injection of astrocyte-derived mitochondria into the peri-infarct cortex 3 days after MCAO promoted neuron survival by increasing the level of phosphorylated AKT and BCL-XL [11]. In neurons, mitochondria are concentrated within the presynaptic nerve terminal. Due to the necessity of long-distance transportation mitochondria can not be replenished quickly after ischemia. The transfer of extracellular mitochondria may, therefore, open a new avenue for neuroprotective strategies.

The beneficial effects of mitochondrial transfer in stroke were first studied by Po-Jui Huang and his colleagues [104]. Transferring exogenous mitochondria via in-situ injection or systemic administration of exogenous mitochondria mitigated cell death both in MCAO rats and OGD neurons and improved the motor performance of rats after MCAO [104]. The grafted mitochondria were traced by pre-labeled with BrdU for their distribution and were internalized by neurons, astrocytes and microglia. Disrupting electron transport or ATPase synthase of the donor mitochondria significantly attenuated the protective effect. Their data supported that in-situ injected mitochondria can be taken by neurons, astrocytes and microglia in MCAO mice, and the intact respiratory activity is essential for the mitochondrial potency on neural protection [104]. A followed-up study on mitochondrial transfer in stroke was performed in Eng H. Lo’s group. Cultured astrocytes were observed to produce functional extracellular mitochondria, which are able to increase the ATP levels and viability of neurons suffered from OGD. Extracellular mitochondria injected in the peri-infarct cortex of MCAO mice were found in neurons. The transplantation of mitochondria resulted in an upregulation of cell-survival-related signals in MCAO mice[11]. The authors suggested that astrocytes have the ability to transfer healthy mitochondria to rescue the damaged neurons after stroke. In their another study, extracellular mitochondria were detected in cerebrospinal fluid (CSF) with decreased mitochondrial membrane potentials in subarachnoid hemorrhage (SAH) rats [105]. In clinic, the similar results were found in SAH patients; and higher membrane potentials of mitochondria in the CSF were correlated with good clinical recovery at 3 months after SAH onset [105]. It is possible that after stroke, neuronal cells transfer mitochondria not only for disposal, but also for recycling and to quickly counteract the energy deficits caused by ischemia.

6. Conclusions and perspectives

Mitochondria disfunction is an early and initiating events in the pathophysiology of stroke [106]. Defected bioenergetics, abnormal mitochondrial morphology and structure, and aberrant mitochondrial dynamics play a central role in the activation of death signaling pathways [107]. Interventions targeting mitochondrial quality control and mitochondrial dynamics by pharmacological agents or genetic modifications have been demonstrated neuroprotective in preclinical studies [49, 108, 109]. Unfortunately, clinical trials using mitochondrial protectants or antioxidants, either alone or in combination with other therapeutic approaches, have been unsuccessful. Targeting mitochondria pharmacologically in the clinic is still challenging. Recently, the evidences of mitochondrial transfer open an entirely new perspective in the intercellular communication. Emerging findings indicate that mitochondria themselves can function as “help-me” signaling in response to diverse extracellular stimulus and recruit adjacent cells to rescue the injured...
cells. Removing the impaired mitochondria and replenishing healthy mitochondria are promising therapeutic approaches to treat hypoxia/ischemia related diseases, especially in CNS which mitochondria are abundance in the distal axonal synapses and dendritic protrusions [110-112]. Though clinical application of mitochondrial transplantation has been performed successfully in pediatric patients suffered from myocardial ischemia-reperfusion injury recently, challenge still remains to implement mitochondrial transfer in clinic widely and safely [113]. Great efforts need to be devoted to investigating the detailed mechanisms on mitochondria release from donor cells and recognition by recipients, the generalizability of the beneficial results, and the ethical implications related to artificially mitochondria transferred. Addressing these hurdles underlying mitochondrial transfer will develop novel manipulation targets for the diseases related to mitochondrial dysfunction.

Acknowledgements

This study was supported by the National Natural Science Foundation of China No. 81601013 to Junjia Tang and No. 81671130 to Qin Hu.

References

[1] Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF (2001). Spontaneous intracerebral hemorrhage. N Engl J Med, 344:1450-1460.
[2] Lapchak PA, Zhang JH (2017). The High Cost of Stroke and Stroke Cytoprotection Research. Transl Stroke Res, 8:307-317.
[3] Simao F, Ustunkaya T, Clermont AC, Feener EP (2017). Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke. Blood, 129:2280-2290.
[4] Adibhatla RM, Hatcher JF (2008). Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Drug Targets, 7:243-253.
[5] Henninger N, Fisher M (2016). Extending the Time Window for Endovascular and Pharmacological Reperfusion. Transl Stroke Res, 7:284-293.
[6] Yang ZS, Mu J (2017). Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection. Med Gas Res, 7:68-73.
[7] Xing C, Hayakawa K, Lo EH (2017). Mechanisms, Imaging, and Therapy in Stroke Recovery. Transl Stroke Res, 8:1-2.
[8] Yang SH, Lou M, Luo B, Jiang WJ, Liu R (2017). Precision Medicine for Ischemic Stroke, Let Us Move Beyond Time Is Brain. Transl Stroke Res.
[9] Vosler PS, Graham SH, Wechsler LR, Chen J (2009). Mitochondrial targets for stroke: focusing basic science research toward development of clinically translatable therapeutics. Stroke, 40:3149-3155.
[10] Huang JL, Manaenko A, Ye ZH, Sun XJ, Hu Q (2016). Hypoxia therapy—a new hope for the treatment of mitochondrial dysfunctions. Med Gas Res, 6:174-176.
[11] Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, et al. (2016). Transfer of mitochondria from astrocytes to neurons after stroke. Nature, 535:551-555.
[12] Hofmeijer J, van Putten MJ (2012). Ischemic cerebral damage: an appraisal of synaptic failure. Stroke, 43:607-615.
[13] Lee JM, Grabb MC, Zipfel GJ, Choi DW (2000). Brain tissue responses to ischemia. J Clin Invest, 106:723-731.
[14] Dharmasaroja PA (2016). Fluid Intake Related to Brain Edema in Acute Middle Cerebral Artery Infarction. Transl Stroke Res, 7:49-53.
[15] van der Worp HB, Macleod MR, Kollmar R, European Stroke Research Network for H (2010). Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab, 30:1079-1093.
[16] Li PY, Wang X, Stetler RA, Chen J, Yu WF (2016). Anti-inflammatory signaling: the point of convergence for medical gases in neuroprotection against ischemic stroke. Med Gas Res, 6:227-231.
[17] Luo T, Park Y, Sun X, Liu C, Hu B (2013). Protein misfolding, aggregation, and autophagy after brain ischemia. Transl Stroke Res, 4:581-588.
[18] Ahsnedt H, Sweet J, Cruden P, Bishop N, Cipolla MJ (2016). Effects of Early Post-Ischemic Reperfusion and tPA on Cerebrovascular Function and Nitrosative Stress in Female Rats. Transl Stroke Res, 7:228-238.
[19] Astrup J, Siesjo BK, Symon L (1981). Thresholds in cerebral ischemia - the ischemic penumbra. Stroke, 12:723-725.
[20] Pisani A, Bonsi P, Calabresi P (2004). Calcium signaling and neuronal vulnerability to ischemia in the striatum. Cell Calcium, 36:277-284.
[21] Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N (2013). Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta, 1833:3448-3459.
[22] Wei H, Li Y, Han S, Liu S, Zhang N, Zhao L, et al. (2016). cPKCgamma-Modulated Autophagy in Neurons Alleviates Ischemic Injury in Brain of Mice with Ischemic Stroke Through Akt-mTOR Pathway. Transl Stroke Res, 7:497-511.
[23] Szabadkai G, Duchen MR (2008). Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda), 23:84-94.
[24] Green DR, Galluzzi L, Kroemer G (2014). Cell biology. Metabolic control of cell death. Science, 345:1250256.
[25] Rugarli EI, Langer T (2012). Mitochondrial quality...
control: a matter of life and death for neurons. EMBO J, 31:1336-1349.
[26] Suliman HB, Plantadosi CA (2016). Mitochondrial Quality Control as a Therapeutic Target. Pharmacol Rev, 68:20-48.
[27] Galluzzi L, Kepp O, Kroemer G (2012). Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol, 13:780-788.
[28] Sims NR, Muyderman H (2010). Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta, 1802:80-91.
[29] Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol, 8:e1000298.
[30] Palade GE (1953). An electron microscope study of the mitochondrial structure. J Histochem Cytochem, 1:188-211.
[31] Tondela D, Grandemange S, Jourdain A, Karbowski M, Mattenberger Y, Herzig S, et al. (2009). SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J, 28:1589-1600.
[32] Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J (2011). Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci U S A, 108:10190-10195.
[33] Ivanina AV, Nesmelova I, Leamy L, Sokolov EP, Sokolova IM (2016). Intermittent hypoxia leads to functional reorganization of mitochondria and affects cellular bioenergetics in marine mussels. J Exp Biol, 219:1659-1674.
[34] Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J (2009). A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci U S A, 106:11960-11965.
[35] Campos JC, Bozi LH, Bechara LR, Lima VM, Ferreira JC (2016). Mitochondrial Quality Control in Cardiac Diseases. Front Physiol, 7:479.
[36] Legros F, Lombes A, Frachon P, Rojo M (2002). Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. Mol Biol Cell, 13:4343-4354.
[37] Bleazard W, McCaffery JM, King EJ, Bale S, Mozdy A, Tieu Q, et al. (1999). The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. Nat Cell Biol, 1:298-304.
[38] Ruthel G, Hollenbeck PJ (2003). Response of mitochondrial traffic to axon demarcation and differential branch growth. J Neurosci, 23:8618-8624.
[39] Bereiter-Hahn J, Voth M (1994). Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria. Microsc Res Tech, 27:198-219.
[40] Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, et al. (2008). Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J, 27:433-446.

Mitochondria in Ischemic Stroke

Sheng ZH, Cai Q (2012). Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci, 13:77-93.
Katoh M, Wu B, Nguyen HB, Thai TQ, Yamasaki R, Lu H, et al. (2017). Polymeric regulation of mitochondrial fission and fusion modifies phenotypes of microglia in neuroinflammation. Sci Rep, 7:4942.
Park J, Choi H, Min JS, Park SJ, Kim JH, Park JJ, et al. (2013). Mitochondrial dynamics modulate the expression of pro-inflammatory mediators in microglial cells. J Neurochem, 127:221-232.
Motori E, Puyal J, Toni N, Ghanem A, Angeloni C, Malaguti M, et al. (2013). Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance. Cell Metab, 18:844-859.
Mopert K, Hajek P, Frank S, Chen C, Kaufmann J, Santel A (2009). Loss of Drp1 function alters OPA1 processing and changes mitochondrial membrane organization. Exp Cell Res, 315:2165-2180.
Saita S, Ishihara T, Maeda M, Iemura S, Natsume T, Mihara K, et al. (2016). Distinct types of protease systems are involved in homeostasis regulation of mitochondrial morphology via balanced fusion and fission. Genes Cells, 21:408-424.
Anand R, Wai T, Baker MJ, Kladt N, Schauss AC, Rugarli E, et al. (2014). The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission. J Cell Biol, 204:919-929.
Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Graber S, et al. (2006). Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J, 25:3900-3911.
Peng C, Rao W, Zhang L, Wang K, Hui H, Wang L, et al. (2015). Mitofusin 2 ameliorates hypoxia-induced apoptosis via mitochondrial function and signaling pathways. Int J Biochem Cell Biol, 69:29-40.
Martorell-Riera A, Segarra-Mondejar M, Munoz JP, Ginet V, Olloquequi J, Perez-Clausell J, et al. (2014). Mfn2 downregulation in excitotoxicity causes mitochondrial dysfunction and delayed neuronal death. EMBO J, 33:2388-2407.
Liu W, Tian F, Kurata T, Morimoto N, Abe K (2012). Dynamic changes of mitochondrial fusion and fission proteins after transient cerebral ischemia in mice. J Neurosci Res, 90:1183-1189.
Kumari S, Anderson L, Farmer S, Mehta SL, Li PA (2012). Hyperglycemia alters mitochondrial fission and fusion proteins in mice subjected to cerebral ischemia and reperfusion. Transl Stroke Res, 3:296-304.
Owens K, Park JH, Gourley S, Jones H, Kristian T (2015). Mitochondrial dynamics: cell-type and hippocampal region specific changes following global cerebral ischemia. J Bioenerg Biomembr, 47:13-31.
Kislin M, Sword J, Fomitcheva IV, Croom D, Pryazhnikov E, Lihavainen E, et al. (2017). Reversible Disruption of Neuronal Mitochondria by Ischemic and
Traumatic Injury Revealed by Quantitative Two-Photon Imaging in the Neocortex of Anesthetized Mice. J Neurosci, 37:333-348.

[55] Zhang N, Wang S, Li Y, Che L, Zhao Q (2013). A selective inhibitor of Drp1, mdivi-1, acts against cerebral ischemia/reperfusion injury via an anti-apoptotic pathway in rats. Neurosci Lett, 535:104-109.

[56] Tang Y, Liu X, Zhao J, Tan X, Liu B, Zhang G, et al. (2016). Hypothermia-induced ischemic tolerance is associated with Drp1 inhibition in cerebral ischemia-reperfusion injury of mice. Brain Res, 1646:73-83.

[57] Grohm J, Kim SW, Mamrak U, Tobaben S, Cassidy-Stone A, Nunari J, et al. (2012). Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ, 19:1446-1458.

[58] Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, et al. (2009). Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol, 11:958-966.

[59] Cho DH, Nakamura T, Fang J, Cieplak P, Godzik A, Gu Z, et al. (2009). S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science, 324:102-105.

[60] Zhou X, Wang HY, Wu B, Cheng CY, Xiao W, Wang ZZ, et al. (2017). Ginkgolide K attenuates neuronal injury after ischemic stroke by inhibiting mitochondrial fission and GSK-3beta-dependent increases in mitochondrial membrane permeability. Oncotarget, 8:44682-44693.

[61] Wang J, Wang P, Li S, Wang S, Li Y, Liang N, et al. (2014). Mdivi-1 prevents apoptosis induced by ischemia-reperfusion injury in primary hippocampal cells via inhibition of reactive oxygen species-activated mitochondrial pathway. J Stroke Cerebrovasc Dis, 23:1491-1499.

[62] Qi X, Qvit N, Su YC, Mochly-Rosen D (2013). A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci, 126:789-802.

[63] Guo X, Sesaki H, Qi X (2014). Drp1 stabilizes p53 on the mitochondria to trigger necrosis under oxidative stress conditions in vitro and in vivo. Biochem J, 461:137-146.

[64] Zhang L, He Z, Zhang Q, Wu Y, Yang X, Niu W, et al. (2014). Exercise pretreatment promotes mitochondrial dynamic protein OPA1 expression after cerebral ischemia in rats. Int J Mol Sci, 15:4453-4463.

[65] Lemasters JJ (2005). Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res, 8:3-5.

[66] Kissova I, Deffieu M, Manon S, Camougrand N (2004). Uth1p is involved in the autophagic degradation of mitochondria. J Biol Chem, 279:39068-39074.

[67] Tal R, Winter G, Ecker N, Kliksyov DJ, Abeliovich H (2007). Aup1p, a yeast mitochondrial protein phosphatase homolog, is required for efficient stationary phase mitophagy and cell survival. J Biol Chem, 282:5617-5624.

[68] Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL, et al. (2015). The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature, 524:309-314.

[69] Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y, et al. (2013). Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy, 9:1321-1333.

[70] Baek SH, Noh AR, Kim KA, Akram M, Shin YJ, Kim ES, et al. (2014). Modulation of mitochondrial function and autophagy mediates carnosine neuroprotection against ischemic brain damage. Stroke, 45:2438-2443.

[71] Shi RY, Zhu SH, Li V, Gibson SB, Xu XS, Kong JM (2014). BNIP3 interacting with LC3 triggers excessive mitophagy in delayed neuronal death in stroke. CNS Neurosci Ther, 20:1045-1055.

[72] Tajiri N, Borlongan CV, Kaneko Y (2016). Cyclosporine A Treatment Abrogates Ischemia-Induced Neuronal Cell Death by Preserving Mitochondrial Integrity through Upregulation of the Parkinson's Disease-Associated Protein DJ-1. CNS Neurosci Ther, 22:602-610.

[73] Qi Z, Dong W, Shi W, Wang R, Zhang C, Zhao Y, et al. (2015). Bcl-2 phosphorylation triggers autophagy switch and reduces mitochondrial damage in limb remote ischemic conditioned rats after ischemic stroke. Transl Stroke Res, 6:198-206.

[74] Zuo W, Zhang S, Xia CY, Guo XF, He WB, Chen NH (2014). Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: the role of inhibition of Drp1 in ischemic brain damage. Neuropharmacology, 86:103-115.

[75] Li Q, Zhang T, Wang J, Zhang Z, Zhai Y, Yang GY, et al. (2014). Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke. Biochem Biophys Res Commun, 444:182-188.

[76] Di Y, He YL, Zhao T, Huang X, Wu KW, Liu SH, et al. (2015). Methylen Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy. Mol Med, 21:420–429.

[77] Cao S, Shrestha S, Li J, Yu X, Chen J, Yan F, et al. (2017). Melatonin-mediated mitophagy protects against early brain injury after subarachnoid hemorrhage through inhibition of NLRP3 inflammasome activation. Sci Rep, 7:2417.

[78] Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH (2004). Nanotubular highways for intercellular organelle transport. Science, 303:1007-1010.

[79] Mathiyanan S, Ji H, Simpson RJ (2010). Exosomes: extracellular organelles important in intercellular communication. J Proteomics, 73:1907-1920.

[80] Plotnikov EY, Khryapenkova TG, Vasileva AK, Marey MV, Galkina SI, Isaev NK, et al. (2008). Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med, 12:1622-1631.
[81] Liu K, Ji K, Guo L, Wu W, Lu H, Shan P, et al. (2014). Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube-like structure-mediated mitochondrial transfer. Microvasc Res, 92:10-18.

[82] Spees JL, Olson SD, Whitney MJ, Prockop DJ (2006). Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A, 103:1283-1288.

[83] Acquistapace A, Bru T, Lesault PF, Figeac F, Coudert AE, le Coz O, et al. (2011). Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells, 29:812-824.

[84] Vallabhaneni KC, Haller H, Dumler I (2012). Vascular smooth muscle cells initiate proliferation of mesenchymal stem cells by mitochondrial transfer via tunneling nanotubes. Stem Cells Dev, 21:3104-3113.

[85] Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. (2012). Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med, 18:759-765.

[86] Lou E, Fujisawa S, Morozov A, Barlas A, Romin Y, Dogan Y, et al. (2012). Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS One, 7:e33093.

[87] Wang X, Gerdes HH (2015). Transfer of mitochondria via tunneling nanotubes rescues apoptotic PC12 cells. Cell Death Differ, 22:1181-1191.

[88] Melentijevic I, Toth ML, Arnold ML, Guasp RJ, Harinath G, Nguyen KC, et al. (2017). C. elegans neurons jettison protein aggregates and mitochondria during early reperfusion for cardioprotection. Am J Physiol Heart Circ Physiol, 313:H2388-H2399.

[89] Chinelli C, Bellucci C, Sartore M, Giorgi D, Spagnoli G, et al. (2017). Mitochondria in ischemic stroke: the role of mitochondrial transfer. Aging and Disease, 8(6):928-941.

[90] Liu F., et al. (2015). Resveratrol preconditioning protects against ischemic stress in human malignant pleural mesothelioma. PLoS One, 7:e33093.

[91] Maeda A, Fadeel B (2014). Mitochondria released by cells undergoing TNF-alpha-induced necroptosis act as danger signals. Cell Death Dis, 5:e1312.

[92] Ahmad T, Mukherjee S, Pattanaik B, Kumar M, Singh S, Kumar M, et al. (2014). Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J, 33:994-1010.

[93] Marlein CR, Zaitseva L, Piddock RE, Robinson S, Edwards D, Shafat MS, et al. (2017). NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood, 130(14):1649-1660.

[94] Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. (2010). Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature, 464:104-107.

[95] Mahrouf-Yorgov M, Augeul L, Da Silva CC, Jourdan M, Rigolet M, Manin S, et al. (2017). Mesenchymal stem cells sense mitochondria released from damaged cells as danger signals to activate their rescue properties. Cell Death Differ, 24:1224-1238.

[96] Clark MA, Shay JW (1982). Mitochondrial transformation of mammalian cells. Nature, 295:605-607.

[97] King MP, Attardi G (1988). Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell, 52:811-819.

[98] Wu TH, Sagullo E, Case D, Zheng X, Li Y, Hong JS, et al. (2016). Mitochondrial Transfer by Photothermal Nanoblade Restores Metabolite Profile in Mammalian Cells. Cell Metab, 23:921-929.

[99] Chang JC, Liu KH, Li YC, Kou SJ, Wei YH, Chuang CS, et al. (2013). Functional recovery of human cells harbouring the mitochondrial DNA mutation MERRF A8344G via peptide-mediated mitochondrial delivery. Neurosignals, 21:160-173.

[100] Macheiner T, Fengler VH, Agreiter M, Eisenberg T, Madeo F, Kolb D, et al. (2016). Magnetomotiotransfer: An efficient way for direct mitochondria transfer into cultured human cells. Sci Rep, 6:35571.

[101] Caicedo A, Fritz V, Brondello JM, Ayala M, Dennemont I, Abdellauai N, et al. (2015). Mitocpection as a new tool to assess the effects of mesenchymal stem/stromal cell mitochondria on cancer cell metabolism and function. Sci Rep, 5:9073.

[102] Mc Cully JD, Cowan DB, Pacak CA, Tournopilius IK, Dayalan H, Levitsky S (2009). Injection of isolated mitochondria during early reperfusion for cardioprotection. Am J Physiol Heart Circ Physiol, 296:H94-H105.

[103] Cowan DB, Yao R, Akurathi V, Snay ER, Thedsanamoorthy JK, Zurakowski D, et al. (2016). Intracoronary Delivery of Mitochondria to the Ischemic Heart for Cardioprotection. PLoS One, 11:e0160889.

[104] Huang PJ, Kuo CC, Lee HC, Shen CI, Cheng FC, Wu SF, et al. (2016). Transferring Xenogenic Mitochondria Provides Neural Protection Against Ischemic Stress in Ischemic Rat Brains. Cell Transplant, 25:913-927.

[105] Chou SH, Lan J, Esposito E, Ning M, Balaj L, Ji X, et al. (2017). Extracellular Mitochondria in Cerebrospinal Fluid and Neurological Recovery After Subarachnoid Hemorrhage. Stroke, 48:2231-2237.

[106] Catanele S, Tarsia J, Fisher M (2017). Acute Ischemic Stroke Therapy Overview. Circ Res, 120:541-558.

[107] Suomalainen A, Battersby BJ (2018). Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol, 19(2):77-92.

[108] Tucker D, Lu Y, Zhang Q (2018). From Mitochondrial Function to Neuroprotection-an Emerging Role for Methyline Blue. Mol Neurobiol, 55(6):5137-5153.

[109] Narayanan SV, Dave KR, Saul I, Perez-Pinzon MA (2015). Resveratrol Preconditioning Protects Against
Cerebral Ischemic Injury via Nuclear Erythroid 2-Related Factor 2. Stroke, 46:1626-1632.

[110] Li Z, Okamoto K, Hayashi Y, Sheng M (2004). The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell, 119:873-887.

[111] Palay SL (1956). Synapses in the central nervous system. J Biophys Biochem Cytol, 2:193-202.

[112] Egawa N, Lok J, Washida K, Arai K (2017).

Mechanisms of Axonal Damage and Repair after Central Nervous System Injury. Transl Stroke Res, 8:14-21.

Emani SM, Piekarski BL, Harrild D, Del Nido PJ, McCully JD (2017). Autologous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury. J Thorac Cardiovasc Surg, 154:286-289.